Gisli Jenkins
Auto-generated profile, based on publicly available information

Gisli Jenkins

Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
HCHarold R. Collard
Harold R. Collard
CRChristopher J. Ryerson
Christopher J. Ryerson
TCTamera J. Corte
Tamera J. Corte
GJGisli Jenkins
Gisli Jenkins
YKYasuhiro Kondoh
Yasuhiro Kondoh
FMFernando J. Martinez
Fernando J. Martinez
Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically significant, respiratory deterioration of unidentifiable cause. The objective of this international working group report on acute exacerbation of idiopathic pulmonary fibrosis was to provide a comprehensive update on the topic. A literature review was conducted to identify all relevant English text publications and abstracts. Evidence-based updates on the epidemiology, etiology, risk factors, prognosis, and management of acute exacerbations of idiopathic pulmonary fibrosis are provided. Finally, to better reflect the current state of knowledge and improve the feasibility of future research into its etiology and treatment, the working group proposes a new conceptual framework for acute respiratory deterioration in idiopathic pulmonary fibrosis and a revised definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis.

1 August 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
PGPeter M George
Peter M George
AWAthol U Wells
Athol U Wells
RJR Gisli Jenkins
R Gisli Jenkins

17 September 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RSR. J. Slack
R. J. Slack
SMS. J. F. Macdonald
S. J. F. Macdonald
JRJames Roper
James Roper
RJR. G. Jenkins
R. G. Jenkins
RHR. J. D. Hatley
R. J. D. Hatley

1 May 2017 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
RJR. Gisli Jenkins
R. Gisli Jenkins
BMBethany B. Moore
Bethany B. Moore
RCRachel C. Chambers
Rachel C. Chambers
OEOliver Eickelberg
Oliver Eickelberg
MKMelanie Königshoff
Melanie Königshoff
EWEric S. White
Eric S. White
Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clinical trials in patients with idiopathic pulmonary fibrosis (IPF), it is imperative that preclinical data packages be robust in their analyses and interpretations to have the best chance of selecting promising drug candidates to advance to clinical trials. The American Thoracic Society has convened a group of experts in lung fibrosis to discuss and formalize recommendations for preclinical assessment of antifibrotic compounds. The panel considered three major themes (choice of animal, practical considerations of fibrosis modeling, and fibrotic endpoints for evaluation). Recognizing the need for practical considerations, we have taken a pragmatic approach. The consensus view is that use of the murine intratracheal bleomycin model in animals of both genders, using hydroxyproline measurements for collagen accumulation along with histologic assessments, is the best-characterized animal model available for preclinical testing. Testing of antifibrotic compounds in this model is recommended to occur after the acute inflammatory phase has subsided (generally after Day 7). Robust analyses may also include confirmatory studies in human IPF specimens and validation of results in a second system using in vivo or in vitro approaches. The panel also strongly encourages the publication of negative results to inform the lung fibrosis community. These recommendations are for preclinical therapeutic evaluation only and are not intended to dissuade development of emerging technologies to better understand IPF pathogenesis.

27 April 2011 in Thorax
Verified
Journal Article
Open access
PDF file
VNV. Navaratnam
V. Navaratnam
KFK. M. Fleming
K. M. Fleming
JWJoe West
Joe West
CSC. J. P. Smith
C. J. P. Smith
RJR. G. Jenkins
R. G. Jenkins
RHR. B. Hubbard
R. B. Hubbard
Background Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the UK and USA. Death registrations and primary care data were used to determine the current trends in IPF incidence in the UK. Because routine clinical data sets were used, the term IPF clinical syndrome (IPF-CS) is used to describe individuals in this study. Methods Age- and stratum-specific death registration rates between 1968 and 2008 were calculated and these were applied to the 2008 population to generate annual standardised expected number of deaths. Annual mortality rate ratios were calculated using Poisson regression. Computerised primary care records were used to determine incidence rates of IPF-CS between 2000 and 2008 stratified by age, sex and geographical region, and survival rates between calendar periods were compared. Results Annual death certificate recording of IPF-CS rose sixfold across the study period from 0.92 per 100 000 in the 1968–1972 calendar periods to 5.10 per 100 000 in the 2006–2008 calendar period, and were higher in men and the older age groups. The incidence of IPF-CS in primary care increased by 35% from 2000 to 2008, with an overall incidence rate of 7.44 per 100 000 person-years (95% CI 7.12 to 7.77). Incidence was higher in men, the older population and in Northwest England. Conclusions The incidence of IPF-CS in primary care and registered deaths from this cause in the UK continues to rise in the 21st century. The current findings suggest that there are >5000 new cases diagnosed each year in the UK.

24 August 2020 in Thorax
Verified
Journal Article
Open access
PDF file
PGPeter M George
Peter M George
SBShaney Barratt
Shaney Barratt
RCRobin Condliffe
Robin Condliffe
SDSujal R Desai
Sujal R Desai
ADAnand Devaraj
Anand Devaraj
LSLisa G Spencer
Lisa G Spencer
The COVID-19 pandemic has led to an unprecedented surge in hospitalised patients with viral pneumonia. The most severely affected patients are older men, individuals of black and Asian minority ethnicity and those with comorbidities. COVID-19 is also associated with an increased risk of hypercoagulability and venous thromboembolism. The overwhelming majority of patients admitted to hospital have respiratory failure and while most are managed on general wards, a sizeable proportion require intensive care support. The long-term complications of COVID-19 pneumonia are starting to emerge but data from previous coronavirus outbreaks such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) suggest that some patients will experience long-term respiratory complications of the infection. With the pattern of thoracic imaging abnormalities and growing clinical experience, it is envisaged that interstitial lung disease and pulmonary vascular disease are likely to be the most important respiratory complications. There is a need for a unified pathway for the respiratory follow-up of patients with COVID-19 balancing the delivery of high-quality clinical care with stretched National Health Service (NHS) resources. In this guidance document, we provide a suggested structure for the respiratory follow-up of patients with clinicoradiological confirmation of COVID-19 pneumonia. We define two separate algorithms integrating disease severity, likelihood of long-term respiratory complications and functional capacity on discharge. To mitigate NHS pressures, virtual solutions have been embedded within the pathway as has safety netting of patients whose clinical trajectory deviates from the pathway. For all patients, we suggest a holistic package of care to address breathlessness, anxiety, oxygen requirement, palliative care and rehabilitation.